BSE: AUROLAB · Healthcare · Pharmaceuticals · Market cap ₹146 Cr
· Prev close ₹232.50
Company profile: not in our data yet
Net margin 11.5% (FY26)
Median of the other 5: 11.1%
Generated Return on capital is 3.4%, 6th of 6 listed peers; Abbott India is first at 44.0%.
Profit, last 4 quarters vs the 4 before: not in our data yet
Generated In FY26 revenue was +58.5% and net profit +92.1% on FY25.
0.9× the peers' median
Peers' median 35.2×
Generated At ₹234.30 the share is priced at 31.2× its earnings per share of ₹7.52 for the 4 quarters Sep 2025 to Jun 2026. The P/E at the FY26 year-end was 46.7×; the other 5 listed peers have a median of 35.2×.
Of profit came in as cash, last 5 fiscal years: not in our data yet
100%: all profit arrived as cash
Generated Operating cash was positive in each of the two years FY25–26; FY26 alone brought in ₹2 cr. Total debt was ₹63 cr at the end of FY26, against a net worth of ₹46 cr.
Held by domestic funds: not in our data yet
In 1 month: not in our data yet
Generated The price is below its 20 and 50-day averages of ₹259 and ₹268.
An earnings call transcript: not in our data yet
Scored statements from the earnings calls: none yet.
Earnings outlook Generated
In Q1 FY27 (Jun 26), net profit was +1,092.0% on the year-earlier quarter; operating margin was 38.9% against 16.2%.
An earnings call transcript: not in our data yet